Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1781383 | 0.88 | L3MBTL1 (0.65) | L3MBTL1ALDH1A1CYP3A4TDP1ALOX15 | |
| SCHEMBL3012179 | 0.82 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1CYP3A4TDP1ALOX15 | |
| SCHEMBL17512318 | 0.80 | ALDH1A1 (0.46) | L3MBTL1ALDH1A1CYP3A4TDP1ALOX15 | |
| SCHEMBL17512317 | 0.80 | ALDH1A1 (0.46) | L3MBTL1ALDH1A1CYP3A4TDP1ALOX15 | |
| SCHEMBL31509357 | 0.79 | MAPT (0.56) | L3MBTL1ALDH1A1CYP3A4TDP1ALOX15 | |
| SCHEMBL1360146 | 0.79 | MAPT (0.56) | L3MBTL1ALDH1A1CYP3A4TDP1ALOX15 | |
| SCHEMBL114077 | 0.79 | KMT2A (0.65) | ALDH1A1CYP3A4TDP1ALOX15KMT2A | |
| SCHEMBL6672075 | 0.79 | L3MBTL1 (0.39) | L3MBTL1ALDH1A1CYP3A4TDP1ALOX15 | |
| SCHEMBL8834690 | 0.78 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1CYP3A4TDP1ALOX15 | |
| SCHEMBL8834685 | 0.78 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1CYP3A4TDP1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2978756-B1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES | Bayer Pharma AG (DE) | 2019-03-27 | — | — | EP | disclosed |
| EP-2978756-B1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES | Bayer Pharma AG (DE) | 2019-03-27 | — | — | EP | disclosed |
| US-10183932-B2 | Substituted oxopyridine derivatives and use thereof cardiovascular disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-22 | — | — | US | disclosed |
| US-10183932-B2 | Substituted oxopyridine derivatives and use thereof cardiovascular disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-22 | — | — | US | disclosed |
| US-10138236-B2 | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-27 | — | — | US | disclosed |
| EP-3197891-B1 | FACTOR XIA-INHIBITING PYRIDOBENZAZEPINE AND PYRIDOBENZAZOCINE DERIVATIVES | Bayer Pharma AG (DE) | 2018-11-21 | — | — | EP | disclosed |
| US-20180086742-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-03-29 | — | — | US | disclosed |
| US-20180086742-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-03-29 | — | — | US | disclosed |
| US-20180086742-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-03-29 | — | — | US | disclosed |
| US-9822102-B2 | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-21 | — | — | US | disclosed |
| US-20160368903-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-22 | — | — | US | disclosed |
| US-20160368903-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-22 | — | — | US | disclosed |
| US-9434690-B2 | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-06 | — | — | US | disclosed |
| US-9434690-B2 | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-06 | — | — | US | disclosed |
| WO-2016046157-A1 | FACTOR XIA-INHIBITING PYRIDOBENZAZEPINE AND PYRIDOBENZAZOCINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016046157-A1 | FACTOR XIA-INHIBITING PYRIDOBENZAZEPINE AND PYRIDOBENZAZOCINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-31 | — | — | WO | disclosed |
| US-20160052884-A1 | Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | disclosed |
| EP-2978756-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2016-02-03 | — | — | EP | disclosed |
| WO-2014154794-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014154794-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10138236-B2 | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives | F13B, TFPI, TFPI2 | L3MBTL1 4265/4885ALDH1A1 3966/4885CYP3A4 336/4885 |
| US-10183932-B2 | Substituted oxopyridine derivatives and use thereof cardiovascular disorders | OGFOD1, VASP, PNPO | L3MBTL1 3798/4885ALDH1A1 1195/4885CYP3A4 46/4885 |
| US-20160052884-A1 | Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders | OGFOD1, PNPO, VASP | L3MBTL1 3576/4885ALDH1A1 1492/4885CYP3A4 60/4885 |
| US-20180086742-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | OGFOD1, PNPO, VASP | L3MBTL1 3576/4885ALDH1A1 1492/4885CYP3A4 60/4885 |
| US-20160368903-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | OGFOD1, PNPO, VASP | L3MBTL1 3576/4885ALDH1A1 1492/4885CYP3A4 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.